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ABSTRACT: We have demonstrated that amino acids E323,Y 324,E 330, and V331 from the factor Va heavy
chain are required for the interaction of the cofactor with factor Xa and optimum rates of prothrombin
cleavage. We have also shown that amino acid region 332-336 contains residues that are important for
cofactor function. Using overlapping peptides, we identiﬁed amino acids D334 and Y335 as contributors to
cofactor activity. We constructed recombinant factor V molecules with the mutations D334 f K and Y335
f F (factor VKF) and D334 f A and Y335 f A (factor VAA). Kinetic studies showed that while factor
VaKF and factor VaAA had a KD for factor Xa similar to the KD observed for wild-type factor Va (factor
VaWT), the clotting activities of the mutant molecules were impaired and the kcat of prothrombinase
assembled with factor VaKF and factor VaAA was reduced. The second-order rate constant of prothrombinase
assembled with factor VaKF or factor VaAA for prothrombin activation was ∼10-fold lower than the second-
order rate constant for the same reaction catalyzed by prothrombinase assembled with factor VaWT.W e
also created quadruple mutants combining mutations in the amino acid region 334–335 with mutations at
the previously identiﬁed amino acids that are important for factor Xa binding (i.e., E323Y324 and E330V331).
Prothrombinase assembled with the quadruple mutant molecules displayed a second-order rate constant
up to 400-fold lower than the values obtained with prothrombinase assembled with factor VaWT. The data
demonstrate that amino acid region 334–335 is required for the rearrangement of enzyme and substrate
necessary for efﬁcient catalysis of prothrombin by prothrombinase.
The mainstay of the hemostasis process is the generation
of thrombin, which in turn promotes the assembly of the
ﬁbrin plug following vascular injury. The prothrombinase
complex is composed of the enzyme, factor Xa, and the
protein cofactor, factor Va, associated in the presence of
divalent metal ions on a membrane surface (1–3). This
complex catalyzes the activation of prothrombin to its active
form, thrombin. Factor Xa alone can activate prothrombin
by two sequential proteolytic cleavages at Arg271 and Arg320
resulting in the intermediates fragment 1·2 and prethrombin
2( 4–14). The overall rate of this reaction is not compatible
with survival; however, incorporation of the cofactor, factor
Va, into prothrombinase reverses the order of the proteolytic
cleavages and increases the catalytic activity of factor Xa
by 5 orders of magnitude (7, 8, 15). The ﬁrst, factor Va-
dependent cleavage at Arg320 produces the intermediate
meizothrombin. Further cleavage at Arg271 generates throm-
bin and fragment 1·2( 4–14). The regulation of this key step
in the blood coagulation cascade has been under intense
investigation for many years.
Plasma factor V circulates as an inactive protein cofactor
with an Mr of 330000 that does not participate in the
prothrombinase complex (16). Factor V must ﬁrst be
activated to factor Va by thrombin through three sequential
proteolytic cleavages at Arg709, Arg1018, and Arg1545 to
produce a heavy chain, composed of amino acid residues
1-709 (Mr ) 105000) and a light chain composed of amino
acid residues 1546-2196 (Mr ) 74000) (17) (Figure 1). The
crystal structure of the bovine factor Va molecule lacking
the entire A2 domain and the acidic COOH terminus of the
heavy chain (factor Vai) has been determined (18). Using
this crystal structure as a template, we have provided a
complete model of the human cofactor in solution (19). This
model allows for the identiﬁcation of the structural perturba-
tions of point mutations on the overall tertiary cofactor
structure.
Both chains of factor Va have been shown to be required
for the interaction of the cofactor with factor Xa (20, 21).
While the binding sites on the light chain remain to be
identiﬁed, several binding sites for factor Xa on the factor
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the inactivation fragments of factor Va by plasmin and
activated protein C (APC) demonstrated that amino acid
region 307-348 is critical for factor Va cofactor function.
A synthetic peptide spanning this amino acid region was
found to be a good inhibitor of factor V/Va clotting activity
[N42R (23)]. This region of factor Va is thought to be
important for cofactor function since it is 82% conserved
among human (25), bovine (26), mouse (27), and porcine
(28) species. Using overlapping synthetic peptides from this
region and recombinant factor Va molecules, we have
demonstrated that amino acid region 323-331 of the factor
Va heavy chain contains critical amino acid residues
responsible for the direct interaction of the cofactor with
factor Xa (23, 29). In addition, our initial data also
demonstrated that amino acid sequence 332IWDYA336, which
is continuous to the factor Xa binding site, was also involved
in the inhibition of prothrombinase activity (23). This study
was undertaken to improve our understanding of the precise
contribution of amino acid region 332-336 of the factor Va
heavy chain to the catalytic efﬁciency of prothrombinase.
EXPERIMENTAL PROCEDURES
Materials, Reagents, and Proteins. Diisopropyl ﬂuoro-
phosphate (DFP), O-phenylenediamine (OPD) dihydrochlo-
ride, N-(2-hydroxyethyl)piperazine-N′-2-ethanesulfonic acid
(Hepes), Trizma (Tris base), and Coomassie Blue R-250 were
purchased from Sigma (St. Louis, MO). Secondary anti-
mouse and anti-sheep IgG coupled to peroxidase were
purchased from Southern Biotechnology Associates Inc.
(Birmingham, AL). L-R-Phosphatidylserine (PS)
1 and L-R-
phosphatidylcholine (PC) were from Avanti Polar Lipids
(Alabaster, AL). Chemiluminescent reagent ECL+ and he-
parin-Sepharose were from AmershamPharmacia Biotech
Inc. (Piscataway, NJ). Normal reference plasma and the
chromogenic substrates Spectrozyme-TH and Spectrozyme-
Xa were from American Diagnostica Inc. (Greenwich, CT).
RecombiPlasTin was purchased from Instrumentation Labo-
ratory (Lexington, MA). Human factor Xa was from Enzyme
Research Laboratories (South Bend, IN). Factor V-deﬁcient
plasma was from Research Proteins Inc. (Essex Junction,
VT). Dansylarginine-N-(3-ethyl-1,5-pentanediyl) amide
(DAPA), RVV-factor V activator, human thrombin, and
human prothrombin were purchased from Haematologic
Technologies Inc. (Essex Junction, VT). Factor V cDNA
(ATCC catalog no. 40515 pMT2-V) was from American
Type Culture Collection (Manassas, VA). All restriction
enzymes were from New England Biolabs (Beverly, MA).
All molecular biology and tissue culture reagents and media
were from Gibco, Invitrogen Corp. (Grand Island, NY), or
as indicated. Monoclonal antibodies RHFVHC17 and
RHFVLC9 and monoclonal antibody RHFV1 coupled to
Sepharose were provided by K. G. Mann (Department of
Biochemistry, University of Vermont, Burlington, VT).
Thrombin Generation Assay Using a Fluorescent Throm-
bin Inhibitor. Thrombin generation assays were performed
using the ﬂuorescent thrombin inhibitor DAPA as de-
scribed previously (23). The buffer used was composed
of 20 mM Tris, 0.15 M NaCl (pH 7.4), and 5 mM CaCl2
(TBS, Ca2+) and was made fresh and ﬁltered before each
use. Fluorescence was measured on a Perkin-Elmer LS-
50B luminescence spectrometer (Perkin-Elmer Corp.,
Norwalk, CT) with a λex of 280 nm, a λem of 550 nm, and
a 500 nm long-pass ﬁlter in the emission beam (Schott
KV-500). The data points were captured using FL WinLab
(Perkin-Elmer Corp.) and subsequently analyzed and
plotted using Prizm (GraphPad, San Diego, CA). Peptides
AP3 and AP4′ were made in the analytical facility of A.
Kurosky (University of Texas, Medical Branch, Galveston,
TX). Peptides IWDYA, AP5, AP4′, AP5m(DYfKF), AP6,
and the control P15H were purchased from New England
Peptide (NEP, Gardner, MA). Peptides were dissolved in
water or buffer. Accurate peptide concentrations were
1 Abbreviations: PS, L-R-phosphatidylserine; PC, L-R-phosphatidyl-
choline; PCPS, small unilamellar phospholipid vesicles composed of
75% PC and 25% PS (w/w); HPLC, high-performance liquid chroma-
tography; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis; PVDF, polyvinylidene diﬂuoride; [OG488]-EGR-hXa,
factor Xa labeled in the active site with Oregon Green 488; factor VaWT,
recombinant wild-type human factor Va; factor VaKF, recombinant
human factor Va with the mutations D334 f K and Y335 f F; factor
VaAA, recombinant human factor Va with the mutations D334 f A and
Y335 f A; factor VaFF, recombinant human factor Va with the mutations
E323 f F and Y324 f F; factor VaMI, recombinant human factor Va
with the mutations E330 f M and V331 f I; factor VI332A, recombinant
human factor Va with the mutation I332 f A; factor VW333A, recombinant
human factor Va with the mutation W333 f A; factor VaFF/KF, quadruple
mutant of recombinant human factor Va with the mutations E323 f F,
Y324 f F, D334 f K, and Y335 f F; factor VaMI/KF, quadruple mutant
of recombinant human factor Va with the mutations E330 f M, V331 f
I, D334 f K, and Y335 f F; factor VaFF/AA, quadruple mutant of
recombinant human factor Va with the mutations E323 f F, Y324 f F,
D334 f A, and Y335 f A; factor VaMI/AA, quadruple mutant of
recombinant human factor Va with the mutations E330 f M, V331 f I,
D334 f A, and Y335 f A.
FIGURE 1: Proteolytic processing of human factor V. Factor V is
composed of 2196 amino acids and has three A domains (A1,
A2, and A3), a connecting B region, and two C domains (C1
and C2). The procofactor is activated following three cleavages
by thrombin at Arg709, Arg1018, and Arg1545. The latter cleavage
is the last to occur and is a prerequisite for light chain formation
and maximum cofactor activity generation. These cleavages
release the active cofactor composed of heavy and light chains
associated in the presence of divalent metal ions, and two
activation fragments. The mutations within a 45-amino acid
region of the A2 domain of the heavy chain of the molecule
that is involved in cofactor activity (hatched box) are indicated
together with the designation for the recombinant mutant factor
V molecules created and used throughout the paper. The black
box preceding cleavage at Arg709 depicts the acidic COOH-
terminal region of factor Va that is essential for optimum cofactor
activity.
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facility of A. Kurosky as detailed previously (30).
Fluorescence Anisotropy Measurements. The ﬂuorescence
anisotropy of [OG488]-EGR-hXa was measured using a
Perkin-Elmer LS-50B luminescence spectrometer in L-format
essentially as extensively described previously (23). Anisot-
ropy measurements were performed in a quartz cuvette under
constant stirring (low) with a λex of 490 nm, a λem of 520
nm, and a long-pass ﬁlter (Schott KV-520) in the emission
beam. All experiments were performed in the dark. The data
obtained were instantly analyzed using FL WinLab (Perkin-
Elmer Corp.).
PCR Site-Directed Mutagenesis and Transient Expression
of Factor V Molecules. Factor VKF was constructed using
the mutagenic primers 5′-C ATT TGG AAG TTT GCA CCT
G-3′ (forward) and 5′-C AGG TGC AAA CTT CCA AAT
G-3′ (reverse) (bold underlined letters identify the mutated
bases) in a two-stage PCR method and characterized as
previously described (29). The resulting amplicon was
subcloned into pGEM-T, and the mutations were conﬁrmed
by DNA sequencing (DNA Analysis Facility, Cleveland State
University). The pGEM-T plasmid was digested with restric-
tion enzymes Bsu36I and XcmI to remove the factor V insert,
and the insert containing the mutation was ligated into pMT2-
FV at the same restriction sites. The remaining recombinant
plasmids were constructed using Stratagene’s QuikChange
XL site-directed mutagenesis kit according to the manufac-
turer’s instructions. Factor VAA was constructed with the
primers 5′-GAG GAA GTC ATT TGG GCC GCC GCA
CCT GTA ATA-3′ (forward) and 5′-TAT TAC AGG TGC
GGC GGC CCA AAT GAC TTC CTC-3′ (reverse). Factor
VMI/KF was constructed with the primers 5′-GAA TAC TTC
ATT GCT GCA GAG ATG GTC ATT TGG AAG TTT
GCA CCT GTA ATA-3′ (forward) and 5′-TAT TAC AGG
TGC AAA CTT CCA AAT GAC CAT CTC TGC AGC
AAT GAA GTA TTC-3′ (reverse). Factor VFF/KF was con-
structed with the primers 5′-CAC ATG AAG ATT TGG
TTT TTC TTC ATT GCT GCA GAG GAA GTC ATT
TGG AAG TTT GCA CCT GTA ATA-3′ (forward) and
5′-TAT TAC AGG TGC AAA CTT CCA AAT GAC TTC
CTC TGC AGC AAT GAA GAA AAA CCA AAT CTT
CAT GTG-3′ (reverse). Factor VMI/AA was constructed with
the primers 5′-GAA TAC TTC ATT GCT GCA GAG ATG
GTC ATT TGG GCC GCC GCA CCT GTA ATA-3′
(forward) and 5′-TAT TAC AGG TGC GGC GGC CCA
AAT GAC CAT CTC TGC AGC AAT GAA GTA TTC-3′
(reverse). Factor VFF/AA was constructed with the primers
5′-CAC ATG AAG ATT TGG TTT TTC TTC ATT GCT
GCA GAG GAA GTC ATT TGG GCC GCC GCA CCT
GTA ATA-3′ (forward) and 5′-TAT TAC AGG TGC AAA
CTT CCA AAT GAC TTC CTC TGC AGC AAT GAA
GAC CAT CCA AAT CTT CAT GTG-3′ (reverse). Factor
VI332A was constructed with the primers 5′-GCT GCA GAG
GAA GTC GCT TGG GAC TAT GCA CCT GTA ATA-3′
(forward) and 5′-TAT TAC AGG TGC ATA GTC CCA
AGC GAC TTC CTC TGC AGC-3′ (reverse). Factor VW333A
was constructed with the primers 5′-GCT GCA GAG GAA
GTC ATT GCG GAC TAT GCA CCT GTA ATA-3′
(forward) and 5′-TAT TAC AGG TGC ATA GTC CGC
AAT GAC TTC CTC TGC AGC-3′ (reverse). In all the
primers, the bases that are bold and underlined represent the
mismatch. The mutations were conﬁrmed by DNA sequenc-
ing (DNA Analysis Facility, Cleveland State University).
Transfection of Recombinant Factor V Molecules into
COS-7L Cells. The COS-7L cell line was maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum and the antibiotics
streptomycin (100 µg/mL) and penicillin (100 IU/mL) in an
atmosphere of 5% CO2 and 95% air at 37 °C. The puriﬁed
wild-type and mutated plasmids were transfected into the
COS-7L cells with Fugene 6 (Roche Diagnostics) as
described previously (29, 31).
Puriﬁcation of Recombinant Proteins. The medium con-
taining the recombinant proteins was centrifuged to remove
any cellular debris. Recombinant factor VKF, factor VAA,
factor VI332A, factor VW333A, and factor VWT were puriﬁed
and quantiﬁed as recently described in detail (32). In some
instances, the quadruple recombinant factor V mutants, factor
VKF, as well as factor VWT were partially puriﬁed and
quantiﬁed as extensively detailed previously (29, 31). The
activities of the partially puriﬁed recombinant factor Va
molecules (29, 31) and the activities of the recombinant
cofactor molecules puriﬁed to homogeneity (32) were similar
and are reported in Table 1. The proteins were stored at -80
°C in small aliquots to prevent repeated freeze-thaw cycles.
The activity and integrity of the recombinant factor V
molecules were conﬁrmed by clotting assays using factor
V-deﬁcient plasma and Western blotting with monoclonal
and polyclonal antibodies.
Prothrombin ActiVation Analysis by Gel Electrophoresis.
Prothrombin (1.4 µM) was incubated in a reaction mixture
containing 20 µM PCPS, 50 µM DAPA, and various
recombinant factor Va molecules at 10 nM (activated with
thrombin at a 1/50 enzyme/substrate ratio) in TBS, Ca2+.
The addition of factor Xa (1 nM) marked the start of the
reaction. Aliquots of the reaction mixture were removed at
selected time points and added to 2 volumes of 0.2 M glacial
acetic acid and treated as described previously (31). The dried
samples were reconstituted in 0.1 M Tris base (pH 6.8), 1%
Table 1: Functional Properties of Recombinant Factor Va Molecules
factor Va species
clotting activity
(units/mg)
a KDapp (nM)
b Km (µM)
c
factor VaPLASMA 2380 ( 150 0.35 ( 0.07 0.16 ( 0.1
factor VaWT 2390 ( 240 0.4 ( 0.1 0.13 ( 0.06
factor VaWTd - 0.24 ( 0.12 0.16 ( 0.1
factor VaKF 440 ( 74 0.58 ( 0.2 0.42 ( 0.06
factor VaKFd - 0.55 ( 0.13 0.6 ( 0.01
factor VaAA 550 ( 70 0.6 ( 0.15 0.62 ( 0.07
factor VaFFd,e - 0.7 ( 0.3 0.10 ( 0.01
factor VaMId,e - 1.8 ( 0.7 0.14 ( 0.01
factor VaFF/KFd ∼30 1.3 ( 0.4 0.66 ( 0.2
factor VaFF/AAd ∼46 2.5 ( 0.8 0.6 ( 0.3
factor VaMI/KFd e30 5.5 ( 1 0.6 ( 0.35
factor VaMI/AAd e30 4.6 ( 0.8 0.4 ( 0.25
factor VaI332A 2103 ( 360 0.33 ( 0.06 0.39 ( 0.07
factor VaW333A 2150 ( 185 0.37 ( 0.08 0.35 ( 0.05
a Two-stage clotting assays of recombinant factor V molecules was
performed as described in Experimental Procedures.
b Apparent dissociation
constants of recombinant factor Va for plasma-derived factor Xa (KDapp)
were determined as described in Experimental Procedures at limiting factor
Xa concentrations (15 pM).
c Apparent Km and kcat (shown in Figure 5B)
values were determined as described in Experimental Procedures at
limiting factor Xa concentrations (5 pM) and saturating concentrations
of factor Va.
d The recombinant molecules were partially puriﬁed and
assayed as described in detail in ref 29.
e The recombinant molecules
were fully characterized in ref 31.
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95 °C. A total of 5 µg of total protein was loaded per lane
and analyzed via 9.5% SDS-PAGE.
Gel Electrophoresis and Western Blotting. Sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
analyses were carried out using 9.5% or 4 to 12% gradient
gels following reduction with 2%  -mercaptoethanol as
described previously (33). In some cases, the protein was
transferred to polyvinylidene diﬂuoride (PVDF) membranes
as described previously (34). Factor Va heavy and light
chains were probed with the appropriate monoclonal anti-
bodies and visualized with chemiluminescence, or the protein
was visualized by staining with Coomassie Brilliant Blue
R-250, followed by destaining in a solution of methanol,
acetic acid, and water. In some experiments, gels were
analyzed by scanning densitometry using UN-SCAN-IT gel
(Silk Scientiﬁc, Orem, UT) as described previously (30, 31).
Assay Measuring Thrombin Formation. The ability of the
recombinant factor V molecules to assemble in the pro-
thrombinase complex was assessed in a discontinuous assay
described in detail elsewhere (31). In short, all recombinant
factor V molecules were activated with thrombin (1/50
enzyme/substrate ratio, 10 min at 37 °C) as described recently
(35). Reaction mixtures contained PCPS vesicles (20 µM),
DAPA (3 µM), factor Xa (varying concentrations), and
recombinant factor Va species in reaction buffer [HEPES,
0.15 M NaCl, 50 nM CaCl2, and 0.01% Tween 20 (pH 7.40)].
DAPA (at twice the concentration of prothrombin) was
included in all mixtures to prevent the action of thrombin
during the course of the assay on factor Va, on prothrombin,
and on itself. The rate of thrombin generation was subse-
quently measured using an excess of chromogenic substrate,
Spectrozyme-TH (0.4 mM). The initial rate of thrombin
generation was analyzed with Prizm (GraphPad), and kinetic
constants were extracted directly from the graphs.
For the calculation of the KD between the factor Va
molecules and factor Xa, assays were performed in the
presence of a limiting factor Xa concentration (15 pM) and
varying concentrations of the recombinant factor Va species
(from 25 pM to 5 nM). For the determination of the kinetic
constants of prothrombinase assembly, Km and kcat, experi-
ments were executed with a limiting amount of factor Xa (5
pM) in the presence of a ﬁxed amount of the various
recombinant factor Va molecules (10 nM) and a varied
amount of substrate (prothrombin). Experiments performed
with the quadruple mutants used saturating concentrations
of factor VFF/KF, factor VMI/KF, factor VFF/AA, and factor
VMI/AA and varying amounts of the substrate prothrombin
(from 25 nM to 4 µM). The concentration of each mutant
cofactor molecule necessary to saturate factor Xa was
calculated with the quadratic equation (eq 1) described in
the literature (36, 37) and given below.
Xabound)(n[Va]T+[Xa]T+KD-
√(n[Va]T+[Xa]T+KD)
2-4n[Va]T[Xa]T)
1⁄2
(1)
where [Va]T and [Xa]T are the total concentrations of factor
Va and factor Xa, respectively. The apparent dissociation
constant (KD) for the bimolecular interaction between factor
Va and factor Xa on a phospholipid surface was obtained
from the functional titration described above and the total
concentration of ligand ([Va]T) modiﬁed as appropriate.
AdditiVe Effect of the Mutations on Prothrombinase
Function. The change in transition-state stabilization free
energy, which measures the effect that mutations in the
cofactor of the prothrombinase complex have on the catalytic
site of the enzyme, was calculated for the quadruple mutants
as extensively described previously (38–42), and recently
(31). In brief, the perturbation to the function of prothrom-
binase assembled with wild-type factor Va (state A) caused
by a mutation in factor Va (state B) affecting the transition
state can be deﬁned in general as follows:
∆∆GB)∆GB-∆GA (2)
Since prothrombinase activity (assembled with each of the
recombinant factor Va proteins) is being measured against
the same substrate (prothrombin), the transition-state stabi-
lization free energy (∆∆G
q
AfB) during catalysis induced by
a mutation in factor Va can be determined from the following
equation:
∆∆G
q
AfB)-RT ln[(kcat⁄Km)B⁄(kcat⁄Km)A] (3)
where R is the universal gas constant (2 cal K-1 mol-1), T
is the absolute temperature (298 K in the experiments
presented here), kcat is the turnover number, and Km is the
Michaelis-Menten constant of the reaction. Once calculated,
these values can be used to determine ∆∆Gint, which reﬂects
the exchange in free energy between the amino acid side
chains manipulated in this study (E323F, Y324F, E330M,
V331I, D334K, Y335F, D334A, and Y335A) by the fol-
lowing equation:
∆∆Gint)∆∆G
q
AfB⁄C-(∆∆G
q
AfB+∆∆G
q
AfC) (4)
A positive value of ∆∆Gint indicates that the interaction
of these amino acid side chains reduces the catalytic
efﬁciency of prothrombinase, while a negative value dem-
onstrates that the mutations are better for prothrombinase,
resulting in an increase in the catalytic efﬁciency of the
enzyme. A value of zero would indicate no effect.
Molecular Dynamics Simulation Setup. Factor VaKF and
factor VaAA were modeled using the recent factor Va model
(PDB entry 1y61) (19). Brieﬂy, amino acid residues Asp334
and Tyr335 were substituted with both lysine and phenyla-
lanine, respectively, or with alanine. The amino acid change
was performed using the “mutate” tool from the SwissPD-
BViewer package (43). Wild-type factor Va was left
unchanged. The molecular dynamics simulation of each
factor Va model consisted of a three-step setup: (1) the
solvation of the protein followed by energy minimization,
(2) position restraint molecular dynamics simulation, and (3)
production run molecular dynamics simulation. Simulations
were run and analyzed using GROMACS version 3.2.1
(44, 45). The system was solvated using the SPC water model
(46). The force used to describe the interaction parameters
was set to GROMOS-87 implemented in GROMACS as
“ffgmx” (47). Molecular topologies for both wild-type factor
Va and factor VaKF were generated using the atom types
described in the “ffgmx” force ﬁeld. Bonds were constrained
using the LINCS algorithm (48). Long-range electrostatic
interactions were evaluated with the particle mesh Ewald
summation method performed in all three dimensions and
using a fourth-order Fourier interpolation on a 1.6 Å spaced
grid (49, 50). Following the minimization procedure, the
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simulation with the restriction that only water molecules were
allowed to move freely and the protein was restrained. The
simulation temperature was set to 300 K and was maintained
using the Berendsen temperature coupling with the coupling
parameter set to 0.1 ps (51). The constant reference pressure
of 1 bar was maintained throughout the simulation using the
Parrinello-Rahman isotropic pressure coupling scheme with
the compressibility set to 4.5 × 10-5 bar-1 (52). Simulations
were run until the systems reached equilibrium. Equilibration
of each system was conﬁrmed when the root-mean-square
displacement of the protein reached a plateau and the drift
was less than 1 Å during a whole nanosecond simulation
time. The last nanosecond of the equilibrated trajectories was
analyzed using tools included in GROMACS (44, 45).
RESULTS
Inhibition of Prothrombinase Function by Synthetic Pep-
tides from the Central Portion of the Factor Va HeaVy Chain.
We have previously shown that a peptide representing amino
acid residues 323-331 inhibits factor Va cofactor activity
(23). We have extensively characterized the important amino
acids from this region by site-directed mutagenesis (29). We
have also shown that under our experimental conditions,
peptides encompassing residues 327-336 (AP5) and 332-341
(AP6) of the factor Va heavy chain also inhibit factor Va
cofactor activity, while the pentadecapeptide P15H (repre-
senting amino acids 337-351 of factor V) did not have any
effect on factor Va activity and was a good negative control.
We have thus hypothesized that the overlapping sequence
between AP5 and AP6 (amino acid motif 332IWDYA336) may
contain amino acids responsible for the inhibition of pro-
thrombinase. To investigate the role of these amino acids as
it pertains to prothrombinase assembly and function, we have
initiated a series of experiments using peptides from this
region (Figure 2). The peptides were assayed for their ability
to inhibit prothrombinase activity in an assay that uses
puriﬁed reagents and a ﬂuorescent thrombin inhibitor (Figure
3A). The data demonstrate that AP5 inhibits prothrombinase
with an IC50 of ∼11 µM [Figure 3A ([)], while the control
peptide (P15H) had no effect on prothrombinase activity
under the conditions employed [Figure 3A (9)], even at
concentrations as high as 500 µM (not shown). Complete
inhibition of prothrombinase by AP5 occurred at 200 µM
peptide (not shown). The Ki for the inhibition of prothrom-
FIGURE 2: Factor Va heavy chain peptides. At the top, the sequence
of N42R is illustrated (part of the hatched box in Figure 1). The
underlined sequence (323-335, 13 amino acids) is the regulatory
amino acid sequence of the factor Va heavy chain. Overlapping
peptides from the central portion of the factor Va heavy chain
[AP3-AP7 (23)] are also shown. The role of the underlined amino
acid region included in the box (i.e., Arg334-Tyr335) and common
to IWDYA, AP5 and AP6, is under investigation here. Bold and
underlined residues are the amino acid residues mutated in this
study.
FIGURE 3: Inhibitory potential of factor Va heavy chain peptides.
(A) Inhibition of prothrombinase activity. Increasing concentrations
of AP5, AP6, P15H, IWDYA, and AP5DYfKF were preincubated
with factor Xa and assayed for prothrombinase activity as described
in Experimental Procedures. P15H (9) represents the control peptide
containing amino acids 337-351 of the human factor Va heavy
chain (see Figure 2 for details). AP5 ([) represents amino acids
327-336 of factor Va. AP5DYfKF (4) represents amino acid
residues 327-336 with residues 334 and 335 mutated from D and
Y to K and F, respectively. IWDYA (0) represents amino acid
residues 332-336 of the human factor Va heavy chain. Data for
AP6 are shown with b. The concentration of peptide given on the
x axis represents its ﬁnal concentration in the prothrombinase
mixture. The data represent the average of the results found in three
independent experiments. The apparent inhibition constant (Ki)
reported in the text is the value calculated from the formula IC50
) Ki(1 + S0/Km)( 53), where Km is the Michaelis-Menten constant
of the reaction in the absence of inhibitor, S0 is the concentration
of prothrombin used, and IC50 is the half-maximal inhibition of
prothrombinase by a given peptide. (B) Inhibition of prothrombinase
assembly. Prothrombinase was assembled with [OG488]-EGR-hXa
(10 nM), PCPS vesicles (10 µM), and increasing concentrations of
human factor Va (up to 25 nM) in the presence of 2 mM Ca2+.
Once a plateau was obtained, the preformed complexes were titrated
with increasing concentrations of P15H (9), AP3 (2), AP4′ (1),
AP5 ([), and AP6 (b). ∆r was calculated as described in
Experimental Procedures and plotted as extensively detailed previ-
ously (23). The data represent all the data points from two
independent experiments performed in triplicate.
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µM. This constant represents the dissociation constant of AP5
for prothrombinase. We have also assessed the effect of AP5
and AP6 for their ability to inhibit the direct binding of factor
Va to [OG488]-EGR-hXa. Both peptides at concentrations as
high as 100 µM were unable to inhibit the direct interaction
of factor Va with [OG488]-EGR-hXa [Figure 3B ([ and b,
respectively)]. In contrast, the nonapeptide control [Figure
3B, AP4′ (1)] was a good inhibitor of the interaction of factor
Va with [OG488]-EGR-hXa as previously described (23). In
addition, AP3 that contains the NH2-terminal portion of AP4′
also inhibited the direct interaction of factor Va with [OG488]-
EGR-hXa [Figure 3B (2)], albeit less efﬁciently than AP4′.
It is noteworthy that AP3 is a noncompetitive inhibitor of
prothrombinase (Figure S1) with respect to substrate, like
AP4′ (23). Kinetic analyses demonstrated that in the presence
of increasing concentrations of inhibitor, the Km remained
constant (0.4 ( 0.06) while the Vmax of the enzymatic reaction
decreased (Figure S1A). Using the mathematical transforma-
tion associated with the Dixon plots, the apparent Ki of
prothrombinase with AP3 was found to be ∼15.6 µM (Figure
S1B). Finally, it is important to underline that control
experiments demonstrated that AP5 did not have any effect
on the catalytic activity of factor Xa, since high concentra-
tions of peptide were unable to inhibit factor Xa activity
toward both a chromogenic substrate and prothrombin (data
not shown).
The mechanism of prothrombinase inhibition by AP5 was
further investigated by examining the effect of the peptide
on the kinetic parameters of prothrombinase assembly and
function (Km and Vmax) in the presence of varying concentra-
tions of the inhibitor (Figure 4). In the presence of increasing
concentrations of peptide, both the apparent Km and Vmax
changed; the inhibitor lowered the Vmax and increased the
Km (Figure 4A). Analysis of the kinetic data using the Dixon
plots demonstrated that AP5 inhibition of prothrombinase
followed a model of linear mixed-type inhibition (Figure 4B).
The apparent Ki of prothrombinase extrapolated from the
graph was 10.5 µM (Figure 4B) which is in good agreement
with the Ki value obtained from the IC50 value determined
above (5.9 µM). The inhibition model of a mixed-type
inhibitor is deﬁned as unequal binding of the inhibitor to E
and ES and suggests that AP5 that contains a portion of the
factor Xa binding site may also interact with prothrombin
in association with prothrombinase (53). However, it is also
possible that binding of prothrombin to prothrombinase alters
the afﬁnity of AP5 for the enzyme.
In view of these results, we have synthesized an additional
peptide (IWDYA) and assayed its ability to inhibit pro-
thrombinase activity. Peptide IWDYA inhibited cofactor
activity, although not completely [Figure 3A (0)]. Even at
500 µM peptide there was still approximately 25% cofactor
activity remaining (not shown). The data demonstrated that
IWDYA has an IC50 of 130 µM which corresponds to a Ki
of 69 µM. Interestingly, AP6 [Figure 3A (b)] has an IC50
of ∼120 µM corresponding to a Ki of 64 µM. The similar
Ki values between AP6 and IWDYA suggest that the
inhibitory effect of the peptides is a consequence of the
shared amino acid sequence 332IWDYA336 [Figure 2 (boxed
sequence)]. However, it is important to note that the data
provided in Figure 3A also demonstrate that while AP6 yields
a Ki value similar to that of pentapeptide IWDYA for
prothrombinase inhibition (∼60 µM), AP5 which also shares
this sequence shows a 10-fold lower Ki value (∼6 µM).
These data suggest that amino acid residues NH2-terminal
to pentapeptide IWDYA are functionally important. This
conclusion is strengthened by our earlier ﬁndings demon-
strating the important contribution of amino acid stretch
227AAEEV331 to factor Va-factor Xa interaction (29). More
recently, we have provided strong evidence supporting the
notion that amino acids Glu330 and Val331 are signiﬁcant
contributors to prothrombinase complex function (31).
To identify the important amino acid residues of this region
for cofactor activity, we have synthesized another peptide
with the sequence DY replaced by KF (AP5DYfKF, AP5m)
and assayed the peptide for prothrombinase inhibition. We
have arbitrarily chosen to mutate these two amino acids
because they are the only charged amino acid residues of
FIGURE 4: Kinetic analyses of prothrombin activation by prothrom-
binase in the presence of AP5. (A) Michaelis-Menten plots.
Prothrombin generation experiments were performed in the absence
(9) and presence of increasing concentrations of AP5 [10 (1), 15
([), and 20 µM( 2)], as described in Experimental Procedures using
prothrombin concentrations varying from 40 nM to 1 µM. Initial
rates of thrombin formation are plotted as a function of substrate
concentration. (B) Analysis of the data using the Dixon plots. The
data were analyzed and plotted as 1/Vo as a function of inhibitor
concentration (AP5, Dixon plots). For mixed-type inhibition, a
Dixon plot of 1/Vo as a function of increasing concentration of
inhibitor is linear at a ﬁxed enzyme and substrate concentration
(53). The apparent inhibition constant (Ki) reported in the text is
the value derived from the intercept of each of the four graphs
(∼10.5 µM). The lines drawn represent the best ﬁt through the
points with an R2 varying from 0.9812 (worst) to 0.9881 (best).
The following concentrations of prothrombin were used in the
experiments: 80 ([), 100 (b), 150 (0), and 200 nM (4).
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amino acids (I332W333) was also established using recombi-
nant technology and shown below. AP5m had an only weak
effect on prothrombinase function with ∼60% cofactor
activity remaining at concentrations of peptide as high as
500 µM [Figure 3A (4)], with a Ki value of ∼530 µM
(assuming an IC50 of ∼1 mM). These data indicate that amino
acid region 334–335 is important for the expression of the
inhibitory potential of AP5. Taken together, the results
indicate that (1) peptide AP5 from the central portion of the
factor Va heavy chain is a potent inhibitor of factor Va
cofactor activity and (2) amino acid region 323-335 (13
amino acids) from the factor Va heavy chain plays an
important role in the optimal expression of prothrombinase
activity (Figure 2).
Expression and ActiVation of Recombinant Human Factor
V Molecules. We next employed a recombinant protein
scheme to further asses the importance of amino acid region
334–335 of the factor Va heavy chain for cofactor activity.
We used one charge reversal mutation (D334K) and one
conservative mutation (Y335F) to obtain recombinant factor
VKF. We have also replaced both amino acids with alanine
to produce factor VAA. In addition, we have combined these
mutations with mutations at the extremities of the factor Xa
binding site on factor Va. We have thus obtained the
quadruple mutants, factor VMI/KF, factor VFF/KF, factor
VMI/AA, and factor VFF/AA (see Figure 1 for more details) (31).
To assess the importance of the other two amino acids of
peptide IWDYA, i.e., I332 and W333, for cofactor function,
we have created two additional mutant molecules with these
amino acids changed to alanine (factor VI332A and factor
VW333A). All eight recombinant factor V molecules along with
wild-type factor V (factor VWT) were expressed, puriﬁed,
and assayed in a two-stage clotting assay, and the results
are reported in Table 1. Factor VaWT displayed normal
clotting activity, compared to plasma-derived factor Va.
Conversely, while factor VaKF and factor VaAA had 5-fold
reduced clotting activity under similar experimental condi-
tions, all the quadruple mutants were practically devoid of
clotting activity (e30 units/mg). We have previously dem-
onstrated that factor VaFF and factor VaMI are impaired in
their interaction with factor Xa (31). Results with these
mutants are reported in Table 1 for comparison. The data
demonstrate that while mutation of amino acid region
334-335 impair clotting activity, these mutations alone are
not enough to completely abolish factor Va clotting activity.
However, combining these mutations with mutations at the
extremities of the previously described factor Xa binding
site results in cofactor molecules that are devoid of clotting
activity. The clotting data obtained with the recombinant
proteins also demonstrate that amino acids I332 and W333 are
not essential for expression of factor Va clotting activity as
the mutant molecules have clotting capabilities comparable
to that of the wild-type molecule.
Effect of Recombinant Factor Va Molecules on Prothrom-
bin ActiVation by Prothrombinase. The capability of the
recombinant factor Va molecules to be incorporated into
prothrombinase and activate prothrombin was investigated
by gel electrophoresis. Prothrombinase assembled with factor
VaWT displayed normal activation pattern compared to the
plasma-derived cofactor with initial cleavage at Arg320
producing fragment 1·2-A (Figure S2), indicative of meizo-
thrombin generation. Activation of prothrombin by pro-
thrombinase assembled with recombinant puriﬁed factor VaKF
or factor VaAA showed delayed thrombin formation as
evidenced by delayed formation of both fragment 1·2-A and
B chain of thrombin (Figure S2). Under similar experimental
conditions, prothrombinase assembled with factor VaFF/KF,
factor VaMI/KF, factor VaFF/AA, and factor VaMI/AA did not
activate prothrombin to any signiﬁcant extent, following a
3 h incubation period (data not shown). These results indicate
that substitution of amino acids 334 and 335 of the factor
FIGURE 5: Prothrombin titrations to determine the kinetic parameters
of prothrombinase assembled with the various recombinant factor
Va species. Thrombin generation experiments were carried out as
described in Experimental Procedures by varying the substrate
concentration. The raw data (hyperbolas) are shown in panel A:
(9 and 0) two different preparations of wild-type factor Va, (O)
factor VaAA,( b) factor VaFF-KF,( 3 and 1) two different preparations
of factor VaKF, (crossed boxes) factor VaMI-AA,( [) factor VaMI-KF,
(9) factor VaFF-AA,( +) factor VaI332A, and (×) factor VaW333A. The
Km values for all cofactor molecules are given in Table 1, while
the kcat values are shown in panel B (min-1). Panel C provides
the second-order rate constants (M-1 s-1). The data represent the
average values found in at least three different titrations for each
recombinant factor Va molecule.
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by factor Xa within prothrombinase assembled with factor
VaKF or factor VaAA.
Kinetic Analyses of Prothrombinase Assembled with
Recombinant Factor Va. The ability of the recombinant factor
Va molecules to be incorporated into prothrombinase was
investigated using an assay employing puriﬁed reagents.
Under similar experimental conditions, factor VaI332A, factor
VaW333A, factor VaKF, and factor VaAA displayed KD values
comparable to the value obtained with the wild-type molecule
(Table 1). Conversely, the afﬁnities of factor VaFF/KF, factor
VaFF/AA, factor VaMI/KF, and factor VaMI/AA were 6-, 10-, 23-,
and 20-fold, respectively, lower than the afﬁnity of factor
VaWT for factor Xa (Table 1). These data demonstrate that
amino acids 332-335 do not participate in the interaction
of the cofactor with factor Xa.
Figure 5 and Table 1 show the original raw data (Figure
5A), the apparent kcat (Figure 5B), the apparent Km (Table
1), and the second-order rate constants (Figure 5C) of
prothrombinase assembled with the recombinant factor Va
molecules. Knowing the KD of each recombinant molecule
for factor Xa (Table 1), we calculated the appropriate amount
of factor Va to saturate factor Xa using the quadratic equation
(eq 1) described in the literature (36, 37) and provided in
Experimental Procedures. Thus, the titrations were performed
under conditions where all factor Xa was saturated with
factor Va, and as a consequence, any observed deﬁciency
in the catalytic activity of prothrombinase was attributed to
a defective factor Va molecule rather than to an impaired
factor Va-factor Xa interaction. The data demonstrate that
prothrombinase assembled with puriﬁed factor VaKF and
factor VaAA was characterized by an ∼10-fold decrease in
second-order rate constants (Figure 5B,C) compared to
prothrombinase assembled with factor VaWT. Prothrombinase
assembled with the quadruple mutant molecules, factor
VaMI/KF, factor VaFF/KF, factor VaMI/AA, and factor VaFF/AA,
demonstrated a signiﬁcant decrease in the kcat and the second-
order rate constant of the enzyme [up to 400-fold decrease
(Figure 5C)]. The kinetic data obtained with the recombinant
proteins also demonstrate that amino acids I332 and W333 are
not required for expression of factor Va cofactor activity
since the kinetic constants obtained with prothrombinase
assembled with these two mutant molecules are similar to
the data obtained with prothrombinase assembled with wild-
type factor Va. Overall, the data show that substitution of
amino acids 334 and 335 in factor Va has an effect on the
catalytic efﬁciency of prothrombinase.
Effect of the Mutations on Prothrombin Catalysis. Pro-
thrombinase is composed of factor Va and factor Xa
assembled on a membrane surface in the presence of divalent
metal ions. We can thus hypothesize that prothrombinase is
an enzyme composed of two subunits: a catalytic subunit
(factor Xa) and a regulatory subunit (factor Va). Any
perturbation in the interaction between the two subunits or
any perturbations in the interaction of prothrombinase with
the substrate caused by a mutation in the regulatory subunit
may inﬂuence (modify) the stability of the catalytic site of
the catalytic subunit. Thus, the consequences of mutations
in factor Va affecting factor Xa catalytic efﬁciency can be
measured relative to the change in the transition-state
stabilization free energy of the enzyme. The kinetic data
showed that the DY f KF/AA mutation in factor Va results
in a decrease in the catalytic efﬁciency of factor Va which
in turn is translated by positive values of ∆∆Gq
WTfKF and
∆∆Gq
WTfAA of 1.24 and 1.5 kcal/mol, respectively (Scheme
1). To quantify the interaction between these mutations and
the mutations in the previously described factor Xa binding
site (31) and their synergistic effects on prothrombinase
function, we have calculated the difference in free energy
of the transition-state analogue (∆∆Gint) for each of the
quadruple mutants according to eqs 3 and 4. We have also
constructed a thermodynamic cycle of prothrombinase
(Scheme 1). The positive value of ∆∆Gint for the combination
of mutations at amino acids 323 and 324 and amino acids
330 and 331 with the DY f KF mutation indicates that these
substitutions in the heavy chain of factor Va are detrimental
to the catalytic activity of prothrombinase.
Structural Consequences of the Mutations. We next used
the model of the factor Va molecule to understand the structural
consequences of the mutations at positions D334 and Y335.I ti s
important to underline that our MD simulations are tentative,
especially with reference to interactions within the A2 domain,
as this region is not present in any crystal structures and is
derived from modeling (19). The MD simulation of factor VaWT
reached equilibrium after 1 ns and was extended for an
additional 1 ns for analysis. The simulation of factor VaKF
reached equilibrium after 2.5 ns, and the simulation was
extended to 3.5 ns for analysis of the last equilibrated
nanosecond. The simulation of factor VaAA reached equilibrium
at 2 ns, and the last 500 ps was used for analysis. Figure 6A
shows the ﬁnal snapshot of factor VaWT with amino acid
residues D334 and Y335 shown as blue sticks. The corresponding
amino acids in factor VaKF [K334 and F335, respectively (Figure
6B)] and in factor VaAA [A334 and A335, respectively (Figure
6C)] are also represented as blue sticks. The MD data show
that the antiparallel  -sheet contained in the region from R321
to V331 (ﬁrst strand) and K365 to T369 (second strand) is preserved
in the case of factor VaWT during the simulation. In contrast, in
the case of factor VaAA and factor VaKF, the  -sheets are
Scheme 1: Thermodynamic Cycle for Prothrombinase
Activity following Substitutions in the Factor Va Heavy
Chain
a
a ∆∆Gint is the free energy of interaction between the side chains of
D334Y335 and E323Y324/E330V331 of the factor Va heavy chain and was
calculated with eqs 3 and 4 described in Experimental Procedures. The
values illustrated on the arrows are the ∆∆Gq values between
recombinant species as indicated. Parallel arrows show the difference
in catalytic efﬁciency between prothrombinase assembled with different
mutant factor Va molecules. Different forms of prothrombinase are
compared for their ability to activate prothrombin.
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 -sheet contains the critical amino acid sequence 323-331
previouslyshowntoregulatefactorVacofactoractivity(22,23,29).
Elongation of the R321-V331/K365-T369  -sheet to R321-A334/
H362-T369 in the factor VaAA molecule positioned H362 in a
conformation that ensured hydrogen bonding with F538, thus
directly affecting the stability of the S528-F538 R-helix. The
S528-F538 helix is a continuation of the amino acid stretch that
contains a secondary binding site of the cofactor for factor Xa
that is located between amino acids 493 and 506 (24).
DISCUSSION
Collectively, through a systematic approach, using both
kinetic studies with synthetic peptides and recombinant
proteins, our data demonstrate that amino acid region
334-335 plays an important role in the expression of factor
Va cofactor activity. Our data also demonstrate the cofactor
requirement for the efﬁcient rearrangement of enzyme (factor
Xa) and substrate (prothrombin) within prothrombinase
necessary for efﬁcient catalysis of prothrombin at two
spatially distinct sites. However, it is important to note that
our study does not provide a deﬁnitive mechanism detailing
the involvement of amino acid region 334-335 of factor
Va in cofactor activity.
The mechanism of inhibition of prothrombinase function
by AP5, AP5DYfKF, AP6, and IWDYA was investigated by
assessing factor Va cofactor activity in the presence of
increasing concentrations of synthetic peptide. These data
show that the IWDYA motif shared by AP5 and AP6
contains the amino acids that account for the inhibitory effect
of the peptides. This is evident in the similar Ki values of
peptides AP6 and IWDYA. AP5 has an ∼10-fold lower Ki
value than AP6 and IWDYA, because it also contains amino
acids Glu330 and Val331, which have been previously shown
to be involved in factor Xa binding (29). Analysis of the
mode of inhibition of prothrombinase by AP5 suggests that
the peptide is a mixed-type inhibitor and interacts with both
prothrombinase and prothrombinase bound to the substrate
(prothrombin). Thus, while it is possible that AP5 interacts
with prothrombinase in the presence and absence of pro-
thrombin, the possibility that AP5 also binds prothrombin
when the enzyme is in complex with the substrate must be
kept in mind. Finally, within the peptide sequence IWDYA,
amino acids D and Y are contributing to its function, since
substitution of these two amino acids with K and F,
respectively (AP5DYfKF), results in the almost complete loss
of the inhibitory potential of AP5.
Site-directed mutagenesis was used to assess the impor-
tance of amino acid region 334-335 from the factor Va
heavy chain during prothrombin catalysis. The data show
that mutating this amino acid region results in a factor Va
molecule that when incorporated into prothrombinase pro-
duces an enzyme with an overall 10-fold decrease in its
second-order rate constant. Since the KD values of factor VaKF
and factor VaAA for factor Xa are similar to the KD of factor
VaWT for the enzyme, the data strongly suggest that the
inability of prothrombinase assembled with factor VaKF and
factor VaAA to function optimally can be explained by the
inability of factor Xa to efﬁciently convert prothrombin to
thrombin because of a diminished number of productive
collisions.
FIGURE 6: Structural analyses of the factor V heavy chain. A portion
of the prothrombin interactive site containing amino acids
D695-Q699 (30, 54, 55) is shown as magenta spheres. The R-helix
contained in S528-F538 is colored red. This region contains a
secondary binding site for factor Xa (24). The  -sheet contained
in the R321-V331/K365-T369 sequence that is important for expres-
sion of factor Va cofactor activity (22, 23, 29) is colored yellow.
The loop contained within the sequence of amino acid residues
400-420 is shown with cyan ribbons. Amino acid residues F538
and H362 are shown as green sticks. S412 is shown as cyan sticks.
N534 and K364 are shown as lime sticks. Amino acid residues Y530
and E330 are shown as olive sticks, and E323 is shown as orange
sticks. The ﬁnal snapshot at 2 ns of factor VaWT is shown in panel
A with amino acid residues D334 and Y335 represented as blue sticks.
Panel B shows the ﬁnal snapshot at 3.5 ns of factor VaKF with the
mutated amino acid residues K334 and Phe335 as blue sticks and
R413 and S412 as cyan sticks. Panel C is a snapshot at 2 ns of factor
VaAA with the mutated amino acid residues A334 and A335 colored
blue.
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type factor Va, factor VaKF, and factor VaAA were able to
offer an explanation both for the similar KD values found
for the interaction of wild-type factor Va and factor VaKF
(or factor VaAA) with factor Xa and for the impaired clotting
and cofactor activity of both mutant molecules. The modeling
data demonstrate that the distances between the CR atoms
of amino acids 334 and 323, 334 and 324, 335 and 323, and
335 and 324 analyzed separately do not change signiﬁcantly
when comparing wild-type factor Va with the mutant
molecules. Thus, there are no changes in the overall
conformation of the segment of amino acids 323-331
because of the mutations. The combined data rather suggest
that the difference in the distance of the centers of mass
between the two amino acid segments observed is due to
the presence of different amino acid side chains that interact
with each other. Coincidentally, the thermodynamic and
kinetic data obtained herein also suggest that combination
of the mutations at the extremities of the factor Xa binding
site in factor Va, 323EY324 (factor VaFF) and 330EV331 (factor
VaMI), with mutations in the 334DY335 region (factor VaKF or
factor VaAA) have an additive detrimental effect on pro-
thrombinase with respect to prothrombin activation. It is also
important to note that replacement of an aspartic acid with
an alanine appeared to be more detrimental to cofactor
activity than replacement with lysine. These data would
suggest that the negative charge per se at residue 334 is not
critical for cofactor activity. Finally, we must point out that
tentative explanations using our theoretical model are sug-
gestive rather than conclusive and await veriﬁcation that will
be obtained from the crystal structure of the recombinant
mutated cofactor molecule.
At this point, it is important to underline the complemen-
tarities of all the data provided in this paper. Our ﬁndings
using the MD simulations demonstrate that in the presence
of the mutations there is a relocation of the COOH-terminal
region of factor VaKF and factor VaAA as compared with the
wild-type cofactor molecule. However, these calculations are
unable to distinguish whether the changes will enhance or
decrease the catalytic efﬁciency of the prothrombinase
complex assembled with the mutated cofactor molecule. On
the other hand, the kinetic, thermodynamic, and molecular
biology data demonstrate a detrimental effect of the mutations
on cofactor activity without providing a structural explana-
tion. Together, the data suggest that the internal rearrange-
ment at the COOH terminus of factor VaKF and factor VaAA
is detrimental to the overall catalytic efﬁciency of factor Xa
as part of prothrombinase. Therefore, the MD simulations
using the only complete structure of factor Va in solution
available in the literature are useful in providing a theoretical
explanation for the decrease in the second-order rate constant
of prothrombinase assembled with the mutant cofactor
molecules.
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SUPPORTING INFORMATION AVAILABLE
Figure S1 shows the kinetic analyses of prothrombin
activation by prothrombinase in the presence of AP3. Panel
A shows the Michaelis-Menten plots, while panel B shows
the mathematical transformation of the data using Dixon
plots. Figure S2 shows prothrombin activation by prothrom-
binase assembled with recombinant factor Va molecules. This
material is available free of charge via the Internet at http://
pubs.acs.org.
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